Detalhe da pesquisa
1.
Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.
Cancer Cell Int
; 23(1): 202, 2023 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37715172
2.
Regulation of CHK1 inhibitor resistance by a c-Rel and USP1 dependent pathway.
Biochem J
; 479(19): 2063-2086, 2022 10 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36240066
3.
Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.
Leukemia
; 38(6): 1223-1235, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38600316
4.
Biallelic TET2 mutations confer sensitivity to 5'-azacitidine in acute myeloid leukemia.
JCI Insight
; 8(2)2023 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36480300